- For Physicians
- For Patients
- Get Involved
Biologic medicines are among the most powerful therapies in use today for patients suffering from cancer, rheumatoid arthritis, multiple sclerosis, and other serious conditions.
Copies of these medicines, known as biosimilars, are now becoming available to U.S. patients, offering them new therapeutic choices at reduced cost.
Yet unlike generic versions of chemical drugs, biosimilars are not exact copies of their reference products. These inherent differences create new safety and regulatory challenges for patients, providers, and policymakers. For example, while highly similar to their reference products, biosimilars are unique medicines which may or not have been tested in or approved for all indications of the originator medicines.
Join CSMS and the Alliance for Safe Biologic Medicines (ASBM) for refreshments and hear experts from the physician and patient communities discuss the science of biosimilars, as well as how healthcare providers and policymakers are working to safely bring their benefits to patients. Check-in and a light dinner will begin at 6 pm; the program will begin promptly at 6:30.
Jeffrey Gordon, MD
President, Connecticut State Medical Society; Medical Director of Hematology-Oncology Services at Day Kimball Hospital (Putnam, CT)
EVP/CEO, Connecticut State Medical Society
Harry Gewanter, MD
Chairman, Alliance for Safe Biologic Medicines (ASBM)
Andrew Spiegel, Esq.
Executive Director, Global Colon Cancer Association
There is no charge to attend the program, but space is limited and advance registration is required.
To register, please contact John Bermudez (email@example.com / 203-865-0587 x122).